Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Prospective Ropeginterferon Alfa-2b Therapy in PV & ET Influences Prothrombotic, Inflammatory and Hypoxia Inducible Factors Activities and Effect of Concomitant DNMT3A Mutation

Jihyun Song, Soo Jin Kim, Yewon Lim, Grace Min, Amanda Smith, Aaron Swomley, Tsewang Tashi, Josef T. Prchal

Blood (2024) 144 (Supplement 1): 6570.

https://doi.org/10.1182/blood-2024-211716

Published: 2024

Journal Articles

Apex Part 2 Trial in Progress: A Phase 2 Open-Label Clinical Study of Bezuclastinib in Adult Patients with Advanced Systemic Mastocytosis

Blood (2024) 144 (Supplement 1): 4569.1.

https://doi.org/10.1182/blood-2024-194550

Published: 2024

Journal Articles

A Phase 1 Study of Avapritinib in Combination with Decitabine in Patients with Systemic Mastocytosis with an Associated Hematologic Neoplasm

Andrew T. Kuykendall, Somedeb Ball, Jason Gotlib, Cecilia Y. Arana Yi, Tsewang Tashi, Raajit Rampal, Daniel J DeAngelo, Virginia O. Volpe, Kristen M. Pettit, Gerard Hoehn, Sasa Dimitrijevic, Rami S. Komrokji, Eric Padron

Blood (2024) 144 (Supplement 1): 4569.2.

https://doi.org/10.1182/blood-2024-211148

Published: 2024

Journal Articles

Apex Part 1: Updated Assessment of Bezuclastinib (CGT9486), a Selective KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM)

Blood (2024) 144 (Supplement 1): 659.

https://doi.org/10.1182/blood-2024-193678

Published: 2024

Journal Articles

Ultra-Sensitive KIT testing Uncovers Previously Undetected KIT mutations in Patients with Indolent Systemic Mastocytosis: Results from the Pioneer Trial

Deepti H. Radia, Tsewang Tashi, Ivan Alvarez-Twose, Patrizia Bonadonna, Hanneke Oude Elberink, Sonia Cerquozzi, Tracy I. George, Guang Yang, Mark Rosenzweig, Hui-Min Lin, Ben Lampson, Rachel L. Erlich, Jason Gotlib

Blood (2024) 144 (Supplement 1): 3164.

https://doi.org/10.1182/blood-2024-207798

Published: 2024

Journal Articles

Paradigm-PV: A Global, Randomized, Multicenter, Two-Arm Phase IV Study to Assess the Efficacy and Safety of Ropeginterferon Alfa-2b in Low- and High-Risk Patients with Polycythemia Vera

Abdulraheem Yacoub, Ghaith Abu-Zeinah, Albert Qin, Weichung Joe Shih, Waleed Da'na, Tsewang Tashi, Oleh Zagrijtschuk, Robert Geller, Harinder Gill

Blood (2024) 144 (Supplement 1): 6626.

https://doi.org/10.1182/blood-2024-199337

Published: 2024

Journal Articles

Quality of Life Evaluation for Patients on Ropeginterferon Alpha-2b Versus Other Best Available Therapies

Brynn Parsegov, Halee Namanny, Maren Campbell, Yue Zhang, Feiyun Yan, Michael Christiansen, Amanda Smith, Tsewang Tashi, Josef T. Prchal

Blood (2024) 144 (Supplement 1): 1791.

https://doi.org/10.1182/blood-2024-204440

Published: 2024

Journal Articles

Safety and Efficacy of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM): Results from Part 1 of the Phase 2 Apex Trial

Pankit Vachhani, Tsewang Tashi, Gary J. Schiller, Stephanie Lee, Miguel Piris Villaespesa, Helena Pomares, Cristina Bulai Livideanu, Jonathan Lambert, Anthony M. Hunter, Tracy I. George, Cristina Papayannidis, Khalid Shoumariyeh, Rita Petroro, Jenna Zhang, Amanda Pilla, Hina Jolin, Rachael Easton, Vinod Pullarkat

Blood (2023) 142 (Supplement 1): 4567.

https://doi.org/10.1182/blood-2023-178885

Published: 2023

Journal Articles

A Phase 1 Study of Avapritinib in Combination with Decitabine in Patients with Systemic Mastocytosis with an Associated Hematologic Neoplasm

Andrew T. Kuykendall, Somedeb Ball, Jason Gotlib, Cecilia Y. Arana Yi, Tsewang Tashi, Raajit K. Rampal, Daniel J. DeAngelo, Virginia O. Volpe, Kristen Marie Pettit, Rami S. Komrokji, Eric Padron

Blood (2023) 142 (Supplement 1): 6441.

https://doi.org/10.1182/blood-2023-184652

Published: 2023

Journal Articles

A Phase 3b, Randomized, Open-Label, Parallel Group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft (P1101) in Adult Patients with Polycythemia Vera

John Mascarenhas, Tsewang Tashi, Firas El Chaer, Victor Priego, Oleh Zagrijtschuk, Albert Qin, Jewell Jessup, Craig Zimmerman, Ray Urbanski, Lucia Masarova

Blood (2023) 142 (Supplement 1): 6444.

https://doi.org/10.1182/blood-2023-189912

Published: 2023

Journal Articles

Real-World Experience of Ropeginterferon-Alfa Treatment of PV and ET - Two Centers Experience

Tsewang Tashi, Brandi N. Reeves, Soo Jin Kim, Hyewon Jeong, Sheh-Li Chen, Brynn Parsegov, Josef T. Prchal

Blood (2023) 142 (Supplement 1): 6397.

https://doi.org/10.1182/blood-2023-191268

Published: 2023

Journal Articles

Predictive Value of Elevated Tryptase and Mediator Symptoms in Systemic Mastocytosis - a Single Center Experience

Tsewang Tashi, Laura Bickel

Blood (2023) 142 (Supplement 1): 6395.

https://doi.org/10.1182/blood-2023-191117

Published: 2023

Journal Articles

Elenestinib, an Investigational, Next Generation KIT D816V Inhibitor, Reduces Mast Cell Burden, Improves Symptoms, and Has a Favorable Safety Profile in Patients with Indolent Systemic Mastocytosis: Analysis of the Harbor Trial

Blood (2023) 142 (Supplement 1): 76.

https://doi.org/10.1182/blood-2023-188904

Published: 2023

Journal Articles

Exploratory Study on Impact of Comorbid Sleep Apnea Treatment in Patients with Polycythemia Vera and Essential Thrombocythemia

Krishna Sundar, Jihyun Song, Soo Jin Kim, Binal Shah, Kimberly Workman, Braxton Smith, Ellen Brooks, Gabrielle Matinkhah, Srinivas K. Tantravahi, Tsewang Tashi, Victor R. Gordeuk, Josef T. Prchal, Brynn Parsegov

Blood (2023) 142 (Supplement 1): 6414.

https://doi.org/10.1182/blood-2023-182884

Published: 2023

Journal Articles

Development of a Comprehensive Program for Evaluation of Hereditary Predisposition to Hematologic Malignancies

Jennie Vagher, Bryan D. Huber, Luke Maese, Archana M Agarwal, Afaf Osman, Ami B. Patel, Tsewang Tashi, Paul J Shami, Tibor Kovacsovics, Julie D. Asch, Charles J. Parker, Srinivas K. Tantravahi

Blood (2022) 140 (Supplement 1): 11468–11470.

https://doi.org/10.1182/blood-2022-170000

Published: 2022

Journal Articles

Preliminary Safety and Efficacy from Apex, a Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Adults with Advanced Systemic Mastocytosis (AdvSM)

Daniel J. DeAngelo, Vinod A. Pullarkat, Miguel Piris-Villaespesa, Tracy I. George, Jay L. Patel, Celalettin Ustun, Prithviraj Bose, Mark L Heaney, Jessica Sachs, Lei Sun, Amanda Pilla, Benjamin Exter, Hina A. Jolin, Tsewang Tashi

Blood (2022) 140 (Supplement 1): 1512–1513.

https://doi.org/10.1182/blood-2022-156311

Published: 2022

Journal Articles

Disease Characteristics of AML Patients with Germline DDX41 Variants

Jennie Vagher, Shobi Venkatachalam, Peng Li, Julie D. Asch, Bryan D. Huber, Tsewang Tashi, Paul J Shami, Tibor Kovacsovics, Luke Maese, Charles J. Parker, Srinivas K. Tantravahi

Blood (2021) 138 (Supplement 1): 3384.

https://doi.org/10.1182/blood-2021-154117

Published: 2021

Journal Articles

A Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Advanced Systemic Mastocytosis (AdvSM)

Jason Gotlib, Tracy I. George, Michael W. Deininger, Tsewang Tashi, Vinod A. Pullarkat, Prithviraj Bose, Francis Payumo, Amanda Pilla, Hina Jolin, Jessica Sachs, Daniel J. DeAngelo

Blood (2021) 138 (Supplement 1): 3636.

https://doi.org/10.1182/blood-2021-145928

Published: 2021

Journal Articles

Pioneer Part 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib in Indolent Systemic Mastocytosis

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-136632

Published: 2020

Journal Articles

Phlebotomy-Induced Iron Deficiency Increases the Expression of Prothrombotic Genes

Jihyun Song, PhD, Adelina Sergueeva, MD, Galina Miasnikova, MD, Soo Jin Kim, MS, Binal N. Shah, PhD, Tsewang Tashi, MD, Xu Zhang, PhD, Perumal Thiagarajan, MD, Victor R. Gordeuk, MD, Josef T. Prchal, MD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-141374

Published: 2020

NARROW

Prospective Ropeginterferon Alfa-2b Therapy in PV & ET Influences Prothrombotic, Inflammatory and Hypoxia Inducible Factors Activities and Effect of Concomitant DNMT3A Mutation

Apex Part 2 Trial in Progress: A Phase 2 Open-Label Clinical Study of Bezuclastinib in Adult Patients with Advanced Systemic Mastocytosis

A Phase 1 Study of Avapritinib in Combination with Decitabine in Patients with Systemic Mastocytosis with an Associated Hematologic Neoplasm

Apex Part 1: Updated Assessment of Bezuclastinib (CGT9486), a Selective KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM)

Ultra-Sensitive KIT testing Uncovers Previously Undetected KIT mutations in Patients with Indolent Systemic Mastocytosis: Results from the Pioneer Trial

Paradigm-PV: A Global, Randomized, Multicenter, Two-Arm Phase IV Study to Assess the Efficacy and Safety of Ropeginterferon Alfa-2b in Low- and High-Risk Patients with Polycythemia Vera

Quality of Life Evaluation for Patients on Ropeginterferon Alpha-2b Versus Other Best Available Therapies

Safety and Efficacy of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM): Results from Part 1 of the Phase 2 Apex Trial

A Phase 1 Study of Avapritinib in Combination with Decitabine in Patients with Systemic Mastocytosis with an Associated Hematologic Neoplasm

A Phase 3b, Randomized, Open-Label, Parallel Group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft (P1101) in Adult Patients with Polycythemia Vera

Real-World Experience of Ropeginterferon-Alfa Treatment of PV and ET - Two Centers Experience

Predictive Value of Elevated Tryptase and Mediator Symptoms in Systemic Mastocytosis - a Single Center Experience

Elenestinib, an Investigational, Next Generation KIT D816V Inhibitor, Reduces Mast Cell Burden, Improves Symptoms, and Has a Favorable Safety Profile in Patients with Indolent Systemic Mastocytosis: Analysis of the Harbor Trial

Exploratory Study on Impact of Comorbid Sleep Apnea Treatment in Patients with Polycythemia Vera and Essential Thrombocythemia

Development of a Comprehensive Program for Evaluation of Hereditary Predisposition to Hematologic Malignancies

Preliminary Safety and Efficacy from Apex, a Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Adults with Advanced Systemic Mastocytosis (AdvSM)

Disease Characteristics of AML Patients with Germline DDX41 Variants

A Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Advanced Systemic Mastocytosis (AdvSM)

Pioneer Part 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib in Indolent Systemic Mastocytosis

Phlebotomy-Induced Iron Deficiency Increases the Expression of Prothrombotic Genes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only